Shinjo Samuel K, Maia Otacílio O, Tizziani Vivian A P, Morita Celso, Kochen Jussara A L, Takahashi Walter Y, Laurindo Ieda M M
Division of Rheumatology, School of Medicine, University of São Paulo, Av. Dr. Arnaldo, 455, Sala 3133, CEP 01246-903, São Paulo, SP, Brazil.
Clin Rheumatol. 2007 Aug;26(8):1248-53. doi: 10.1007/s10067-006-0478-9. Epub 2007 Jan 31.
Chloroquine diphosphate has been used in the treatment of various rheumatic diseases, including rheumatoid arthritis. The most important of its side effects is retinopathy. If not diagnosed early, this lesion can evolve into irreversible bull's eye maculopathy and visual loss. The aim of this study was to define the outcome of chloroquine-induced maculopathy after cessation of chloroquine therapy and also to identify the risk factors involved in case of retinopathy evolution. The design of this cohort study was longitudinal and retrospective. Over the period spanning 2000 to 2005, out of 607 medical records of patients with rheumatoid arthritis followed in our Division of Rheumatology, 27 had been diagnosed with chloroquine-induced maculopathy through clinical funduscopy with pupil dilation. In all cases, there was immediate chloroquine intake cessation. After a mean time of 5 years, 16 of these patients were available for follow-up and underwent a new ophthalmologic evaluation by funduscopy, using biomicroscopy and angiofluorescein when necessary. Sequelae maculopathy were reconfirmed in all 16 cases, but progression to advanced stage (bull's eye maculopathy) was found in half of the cohort, even though chloroquine had been suspended. All patients complained of visual alterations, but without progression. Comparison between patient groups with and without bull's eye maculopathy revealed a statistically significant longer rheumatoid arthritis disease history in the former group. Also, the bull's eye group had higher dose intakes of chloroquine and over a longer period compared to the other group, but not statistically significant. This study corroborates the progression of maculopathy even after cessation of chloroquine intake, pointing out the need for careful screening in the high-risk patients. Furthermore, it indicates that duration of rheumatoid arthritis disease could be a possible factor linked to worse prognosis of chloroquine-induced maculopathy.
磷酸氯喹已被用于治疗包括类风湿性关节炎在内的各种风湿性疾病。其最重要的副作用是视网膜病变。如果不及早诊断,这种病变可发展为不可逆的牛眼黄斑病变并导致视力丧失。本研究的目的是确定停止氯喹治疗后氯喹所致黄斑病变的转归,并确定视网膜病变进展情况下的危险因素。这项队列研究的设计是纵向和回顾性的。在2000年至2005年期间,在我们风湿病科随访的607例类风湿性关节炎患者的病历中,有27例通过散瞳临床眼底检查被诊断为氯喹所致黄斑病变。所有病例均立即停止服用氯喹。平均5年后,其中16例患者可供随访,并接受了新的眼底检查眼科评估,必要时使用生物显微镜和荧光素血管造影。所有16例病例均再次确诊有黄斑病变后遗症,但尽管已停用氯喹,仍有一半队列进展至晚期(牛眼黄斑病变)。所有患者均主诉有视力改变,但无进展。有牛眼黄斑病变和无牛眼黄斑病变的患者组之间的比较显示,前一组类风湿性关节炎病史在统计学上显著更长。此外,与另一组相比,牛眼组氯喹的摄入量更高且服用时间更长,但无统计学意义。本研究证实即使停止服用氯喹后黄斑病变仍会进展,指出对高危患者进行仔细筛查的必要性。此外,它表明类风湿性关节炎的病程可能是与氯喹所致黄斑病变预后较差相关的一个可能因素。